AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.9 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Predictive value of bleeding risk scores in elderly patients with atrial fibrillation and oral anticoagulation

Pablo Domínguez-Erquicia1,2Sergio Raposeiras-Roubín1,2( )Emad Abu-Assi1,2Andrea Lizancos-Castro1Jose A Parada-Barcia1André González-García1Ana Ledo-Piñeiro1Vanesa Noriega-Caro1Carla Iglesias-Otero1Andrés Íñiguez-Romo1,2
Department of Cardiology, University Hospital Álvaro Cunqueiro, Vigo, Spain
Health Research Institute Galicia Sur, Vigo, Spain
Show Author Information

Abstract

BACKGROUND

The predictive value of bleeding risk scores for atrial fibrillation in older patients is not as well known. The goal of this study was to evaluate the predictive value of HASBLED, ORBIT and ATRIA for major bleeding (MB) and intracranial hemorrhage (ICH) in patients ≥ 75 years with atrial fibrillation and oral anticoagulation (OAC).

METHODS

A retrospective unicenter study including patients ≥ 75 years with atrial fibrillation (AF) and OAC. A total of 7613 patients ≥ 75 years with AF and OAC included between 2014 and 2018 (registry: NCT04364516). We analyzed the discriminative value of HASBLED, ATRIA and ORBIT scores for bleeding endpoints (major bleeding as primary endpoint and intracerebral hemorrhage as secondary). Cox regression was used to predict major bleeding with each scale and also for searching other variables potentially predictor of major bleeding. Model discrimination was assessed using Harrell’s C-statistic. Calibration was assessed with goodness-of-fit test proposed by Gronnesby and Borgan.

RESULTS

During a mean follow up of 4.0 years (IQR: 2.4–5.7 years), 729 patients developed MB (2.61 per 100 patients/year) and 243 patients developed ICH (0.85 per 100 patients/year). Three scores showed a low discrimination for major bleeding, being ORBIT the best (HASBLED C statistic = 0.557; ATRIA C statistic = 0.568; ORBIT C statistic = 0.595) and also a low discrimination for ICH (HASBLED C statistic = 0.509; ATRIA C statistic = 0.522; ORBIT C statistic = 0.526). Among the variables that are part of the scores and other baseline characteristics, after multivariable adjustment only sex (male), dementia, prior admission for bleeding, anemia and liver disease were found as a predictors of MB.

CONCLUSIONS

In older patients under oral anticoagulation with atrial fibrillation, the risk scores HASBLED, ATRIA and ORBIT showed a weak discrimination for major bleeding and intracranial hemorrhage. Therefore, other better alternatives should be evaluated for this purpose.

Electronic Supplementary Material

Download File(s)
JGC-202301-001R1Supp.pdf (129.8 KB)

References

[1]
Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; ehaa612.
[2]

Fumagalli S, Said SAM, Laroche C, et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). JACC Clin Electrophysiol 2015; 1: 326−334.

[3]

Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093−100.

[4]

O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36: 3258−3264.

[5]

Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395−401.

[6]

Shah SJ, Singer DE, Fang MC, et al. Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2019; 12: e006212.

[7]

Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692−694.

[8]

Nieuwlaat R, Capucci A, Camm AJ, et al; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422−2434.

[9]

Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015; 38: 555−561.

[10]

Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 861−867.

[11]

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883−891.

[12]

Gao X, Cai X, Yang Y, et al. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2021; 8: 757087.

[13]

Bassand JP, Apenteng PN, Atar D, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol 2021; 17: 19−38.

[14]
Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015; 65: 635–642.
[15]

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955−962.

[16]

Schäfer A, Flierl U, Berliner D, Bauersachs J. Anticoagulants for stroke prevention in atrial fibrillation in elderly patients. Cardiovasc Drugs Ther 2020; 34: 555−568.

[17]

Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509−1524.

[18]

Bo M, Grisoglio E, Brunetti E, et al. Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. Eur J Intern Med 2017; 41: 18−27.

[19]

Burgess S, Crown N, Louzada ML, et al. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. J Thromb Haemost 2013; 11: 1647−1654.

[20]

Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 2008; 6: 1−11.

[21]

Cobas Paz R, Raposeiras Roubín S, Abu Assi E, et al. Impact of anticoagulation in patients with dementia and atrial fibrillation. Results of the CardioCHUVI-FA registry. Rev Esp Cardiol (Engl Ed) 2020; 73: 877−884.

[22]

Domínguez-Erquicia P, Raposeiras-Roubín S, Abbu-Assi E, et al. Incidence, predictors of bleeding and prognosis of bleeding in anticoagulated nonagenarian patients with atrial fibrillation. Int J Cardiol 2021; 327: 217−222.

[23]

Proietti M, Romiti GF, Raparelli V, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1, 187, 000 patients. Ageing Res Rev 2022; 79: 101652.

[24]

Ohta M, Hayashi K, Mori Y, et al. Impact of frailty on bleeding events related to anticoagulation therapy in patients with atrial fibrillation. Circ J 2021; 85: 235−242.

Journal of Geriatric Cardiology
Pages 684-692
Cite this article:
Domínguez-Erquicia P, Raposeiras-Roubín S, Abu-Assi E, et al. Predictive value of bleeding risk scores in elderly patients with atrial fibrillation and oral anticoagulation. Journal of Geriatric Cardiology, 2023, 20(9): 684-692. https://doi.org/10.26599/1671-5411.2023.09.002

548

Views

36

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics

Published: 28 September 2023
© 2023 JGC All rights reserved
Return